SQZ Biotechnologies has successfully adopted the established Milliflex® Rapid ATP Bioluminescence based RMM (Rapid Microbiological Method) technology platform from MilliporeSigma to support 3 independent first-in-human (FIH) programs involving autologous cell therapies, including products derived from on RBCs as well as products derived from mixtures of immune cells (B cells, T cells, NK cells, and monocytes). Download the poster to learn more.